Foley Hoag Advises CutisPharma in $20M Financing Round

January 15, 2015

Foley Hoag recently advised CutisPharma, Inc., a privately held specialty pharmaceutical company, in its $20 million equity financing round.

Based in Wilmington, Mass., CutisPharma focuses on the development and commercialization of value-added proprietary pharmaceutical products and technologies in the prescription compounding sector of the healthcare industry. Its product line and development efforts are focused on providing optimized alternatives for the preparation of nearly 20 million compounded prescriptions by offering FIRST® Unit-of-Use Prescription Compounding Kits. Use of these branded kits benefits all key stakeholders, including physicians, pharmacists and patients. Several U.S. patents have been issued to CutisPharma, with additional patents pending.

Foley Hoag attorneys Bob Warren, Jen Audeh, Sarah Mattern, Arlene BenderNicola Lemay and Kip Cawley advised CutisPharma on the transaction.

About Foley Hoag LLP

Foley Hoag provides innovative, strategic legal services to public, private and government clients across the globe. We have premier capabilities in the life sciences, healthcare, technology, energy, professional services and private funds fields, and in cross-border disputes. The diverse backgrounds, perspectives and experiences of our lawyers and staff contribute to the exceptional senior level service we deliver to clients ranging from startups to multinational companies to sovereign states. For more information, visit www.foleyhoag.com or follow @FoleyHoag on Twitter.